Search Orphan Drug Designations and Approvals
-
| Generic Name: | ruxolitinib | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | JAKAFI | ||||||||||||||||
| Date Designated: | 11/03/2016 | ||||||||||||||||
| Orphan Designation: | Treatment of graft versus host disease | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Incyte Corporation 1801 Augustine Cut-Off Wilmington, Delaware 19803 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | ruxolitinib |
|---|---|---|
| Trade Name: | JAKAFI | |
| Marketing Approval Date: | 05/24/2019 | |
| Approved Labeled Indication: | Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. | |
| Exclusivity End Date: | 05/24/2026 | |
| Exclusivity Protected Indication* : | Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. | |
| 2 | Generic Name: | ruxolitinib |
|---|---|---|
| Trade Name: | Jakafi | |
| Marketing Approval Date: | 09/22/2021 | |
| Approved Labeled Indication: | Treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older | |
| Exclusivity End Date: | 09/22/2028 | |
| Exclusivity Protected Indication* : | Treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older | |
| 3 | Generic Name: | ruxolitinib |
|---|---|---|
| Trade Name: | Jakafi XR | |
| Marketing Approval Date: | 05/01/2026 | |
| Approved Labeled Indication: | treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older; and treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older | |
| Exclusivity End Date: | TBD | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







